Clinical trial NCT02127710: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Official title: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Papillary Renal Cell Cancer
Keywords: AZD6094
Savolitinib
Papillary Renal Cell Cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: SCRI Development Innovations, LLC
First posted: 2014-05-01
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated.

An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Detailed description: The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled. This group is considered sufficient to provide preliminary assessment of the anti-tumour activity of AZD6094 in the form of non-binding futility analysis.

If ≤ 2 tumour responses are observed in the first 20 evaluable patients termination of the study will be considered taking into account the relevant molecular profile of the patients and additional information from related studies in the drug development programme.

All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.

Following the baseline assessment, efficacy will be assessed by objective tumour assessments every 6 weeks (±7 days), for the first 12 months and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1 There will be a data cut-off after all patients have completed at least 12 weeks of treatment with AZD6094 or withdrawn. The database will be locked and data analysis will be performed on this dataset.

Any patients still receiving study drug at the time of data cut-off will be able to continue to receive AZD6094 while deriving clinical benefit. Such patients will continue to be monitored for the occurrence of serious adverse events up to 28 days after the last dose of AZD6094.

After database lock (DBL) tumour assessments will be performed every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1.

Patients discontinuing treatment due to documented disease progression will enter a survival follow-up period, where they will be followed for the initiation of subsequent anti-cancer therapies every 3 months until death, loss to follow-up or withdrawal of consent, whichever comes first.

Patients discontinuing treatment prior to documented disease progression will enter a progression-free survival follow-up period where they will continue to have disease assessments every 6 weeks (±7 days) for the first 12 months of follow-up and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1, death, loss to follow-up or withdrawal of consent, whichever comes first. After DBL, tumour assessments will be performed in the progression free survival patient population every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1

Eligibility criteria: Inclusion criteria

1. Provision of informed consent prior to any study specific procedures, sampling and analyses.
2. Histologically confirmed PRCC, which is locally advanced or metastatic.
3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by a central laboratory and other biomarker
4. Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. At least one lesion, not previously irradiated, and not chosen for a biopsy if performed during the screening period that can be accurately measured at baseline and which is suitable for accurate repeated measurements.
7. Adequate hematological function defined as:

   1. Absolute neutrophil count ≥1500/μL
   2. Haemoglobin ≥9 g/dL
   3. Platelets ≥100,000/μL
8. Adequate liver function defined as:

   1. Alanine aminotransferase and aspartate aminotransferase ≤2.5 x the upper limit of normal (ULN)
   2. Total bilirubin ≤1.5 x ULN
9. Adequate renal function defined as glomerular filtration rate ≥ 40 mL/min,
10. Adequate coagulation parameters, defined as International Normalisation Ratio \<1.5 x ULN or activated partial thromboplastin time \<1.5 x ULN.
11. Patients with known tumor thrombus or deep vein thrombosis are eligible if stable on low molecular weight heparin for ≥4 weeks.
12. Females should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
13. Male patients should be willing to use barrier contraception, i.e. condoms.
14. Ability to swallow and retain oral medications.
15. Predicted life expectancy ≥12 weeks.
16. Aged at least 18 years.
17. Willingness and ability to comply with study and follow-up procedures.
18. Ability to understand the nature of this study and give written informed consent.

Exclusion criteria

1. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents \<21 days of the first dose of study treatment. Most recent targeted therapy \<14 days of the first dose of study treatment.
2. Unresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events Grade 1 at the time of starting study treatment with the exception of alopecia.
3. Prior or current treatment with a cMet inhibitor
4. Strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), strong inhibitors of cytochrome P450 1A2 (CYP1A2), or CYP3A4 substrates with a narrow therapeutic range within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
5. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy
6. Major surgical procedures ≤28 days of beginning study drug or minor surgical procedures ≤7 days. No waiting is required following port-a-cath placement.
7. Previously untreated brain metastases.
8. Current leptomeningeal metastases or spinal cord compression due to disease.
9. Acute or chronic liver or pancreatic disease.
10. Uncontrolled diabetes mellitus.
11. Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy
12. Any of the following cardiac diseases currently or within the last 6 months:

    1. Unstable angina pectoris
    2. Congestive heart failure (New York Heart Association ≥ Grade 2)
    3. Acute myocardial infarction
    4. Stroke or transient ischemic attack
13. Inadequately controlled hypertension (i.e., systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg) (patients with values above these levels must have their blood pressure controlled with medication prior to starting treatment).
14. Mean resting correct QT interval (QTc) \>470 msec obtained from triplicate electrocardiagrams
15. Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block, second degree heart block, PR interval \>250 msec.
16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family history of unexplained sudden death under 40 years of age or any concomitant medications known to prolong QT interval.
17. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.
18. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
19. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
20. Presence of other active cancers, or history of treatment for invasive cancer ≤5years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
21. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

Primary outcomes:
measure: Objective Response Rate (RECIST Version 1.1)
timeFrame: Up to 12 months
measure: Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set
timeFrame: 12 Months
measure: Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set
timeFrame: 12 Months
Secondary outcomes:
measure: Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set
timeFrame: Up to 12 months
measure: Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set
timeFrame: Up to 12 months
measure: Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set
timeFrame: Up to 12 months
measure: Overall Survival Stratified by c-MET Status in the Safety Analysis Set
timeFrame: Up to 12 months
measure: Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set
timeFrame: 12 Weeks (at 12 weeks timepoint)
measure: Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.
timeFrame: 12 Weeks (at 12 week timepoint)
measure: Duration of Response
timeFrame: Up to 12 months
measure: Peak Plasma Concentration of AZD6094 Following Single Dose
timeFrame: 24 Hours
measure: Time to Peak Plasma Concentration of AZD6094 After Single Dose
timeFrame: 24 Hours
measure: Apparent Volume of Distribution of AZD6094 Following Single Dose
timeFrame: 24 Hours
measure: Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose
timeFrame: 24 Hours
measure: Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)
timeFrame: 24 Hours
measure: Apparent Total Clearance of AZD6094 From Plasma After Single Dose
timeFrame: 24 Hours
measure: Mean Residence Time of AZD6094 After Single Dose
timeFrame: 24 Hours
measure: Elimination Half-Life of AZD6094 After Single Dose
timeFrame: 24 Hours
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Research Site
state: Alabama
city: Duarte
country: United States
facility: Research Site
state: California
city: Palo Alto
country: United States
facility: Research Site
state: California
city: Fort Myers
country: United States
facility: Research Site
state: Florida
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: Iowa City
country: United States
facility: Research Site
state: Iowa
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: Detroit
country: United States
facility: Research Site
state: Michigan
city: New York
country: United States
facility: Research Site
state: New York
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Nashville
country: United States
facility: Research Site
state: Tennessee
city: Dallas
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Calgary
country: Canada
facility: Research Site
state: Alberta
city: Edmonton
country: Canada
facility: Research Site
state: Alberta
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Barcelona
country: Spain
facility: Research Site
city: Cambridge
country: United Kingdom
facility: Research Site
city: Glasgow
country: United Kingdom
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
city: Manchester
country: United Kingdom
facility: Research Site
Study officials:
affiliation: Sarah Cannon Research Institute United Kingdom
name: Henrik-Tobias Arkenau, MD,PhD
role: STUDY_CHAIR
References: